GATA2 and acute myeloid leukemia: GATA2 deficiency has been reported in association with IA both prior to chemotherapy or HSCT for MDS/AML and, more commonly, during or following the execution of these treatment modalities [174,180,401,402]; as explained in the proposed criteria, the latter state renders the distinction between infection due to iatrogenesis vs. inherent susceptibility inconclusive.